Morning Briefing
Summaries of health policy coverage from major news organizations
More Than One-Third Of Americans Take A Medication That Has Depression As Potential Side Effect
The New York Times: Common Drugs May Be Contributing To Depression
Could common prescription medications be contributing to depression and rising suicide rates? Over one-third of Americans take at least one prescription drug that lists depression as a potential side effect, a new study reports, and users of such drugs have higher rates of depression than those who don’t take such drugs. (Rabin, 6/13)
Los Angeles Times: Are Prescription Medications Making Americans Depressed?
The incidence of depression has been rising in the U.S. for more than a decade. So has Americans’ reliance on prescription medications that list depression as a possible side effect. Coincidence? Perhaps not, according to a new study in the Journal of the American Medical Assn. Using 10 years of data collected from more than 26,000 Americans, researchers reported a significant link between the use of medications with the potential to cause depression and the chances of becoming depressed. (Kaplan, 6/12)
NPR: Many Common Drugs May Be Making People Depressed
The list includes a wide range of commonly taken medications. Among them are certain types of proton pump inhibitors (PPIs) (used to treat acid reflux), beta blockers, anxiety drugs, painkillers including ibuprofen, ACE inhibitors (used to treat high blood pressure), and anti-convulsant drugs. "The more of these medications you're taking, the more likely you are to report depression," says study author Mark Olfson, a professor of psychiatry at Columbia University. (Aubrey, 6/12)
In related news —
The New York Times: How Cognitive Behavior Therapy May Help Suicidal People
After a week of devastating news about suicide, there has been much discussion of the need for people who may be thinking of ending their lives to reach out for help. But some people who are suffering may be skeptical that therapy could make a difference. Research has demonstrated the effectiveness of cognitive behavior therapy, or C.B.T., in treating suicidal individuals and decreasing subsequent attempts. A 2016 review of 15 randomized controlled trials found that C.B.T. “is a useful strategy in the prevention of suicidal cognitions and suicidal behaviors.” (Beck, 6/13)
Sacramento Bee: Here’s What The Suicide Epidemic Looks Like In California
Nearly 4,300 Californians killed themselves in 2016, a 50 percent increase from 2001, according to the latest figures from the U.S. Centers for Disease Control. The suicide rate rose from 8.2 suicides per 100,000 residents to 10.9 suicides per 100,000 residents over the same time period. (Reese, 6/13)
Los Angeles Times: Psychedelic Drugs Change Brain Cells In Ways That Could Help Fight Depression, Addiction And More
Psychedelic drugs’ mind-expanding properties may be rooted in their ability to prompt neurons to branch out and create new connections with other brain cells, new research has found. This discovery may explain why psychedelic drugs appear to be a valuable treatment for a wide range of psychiatric diseases, scientists said. In test tubes as well as in rats and flies, psychedelic drugs as diverse as LSD, ecstasy, psilocybin and ketamine all share this knack for promoting neural “plasticity,” the ability to forge new connections (called neurites) among brain cells. In particular, the drugs appeared to fuel the growth of dendritic spines and axons, the appendages that brain cells of all sorts use to reach out in the darkness and create connections, or synapses, with other brain cells. (Healy, 6/12)
California Healthline: When Erratic Teenage Behavior Means Something More
Mary Rose O’Leary has shepherded three children into adulthood, and teaches art and music to middle-school students. Despite her extensive personal and professional experience with teens, the Eagle Rock, Calif., resident admits she’s often perplexed by their behavior. “Even if you have normal kids, you’re constantly questioning, ‘Is this normal?’” says O’Leary, 61. (Bazar, 6/11)
